Blood levels of CA19-9 and carcinoembryonic antigen (CEA) were 5.8 ng/mL and 50 IU/mL, respectively, which gradually increased during the course of treatment, suggesting pancreatic cancer progression. The gene discussed is CEACAM5; the disease is pancreatic neoplasm.